During the past decade, STZ Eyetrial conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "STZ Eyetrial" are "Geographic Atrophy" (2 trials), "Geographic Atrophy Secondary to Age-related Macular Degeneration" (1 trials) and "Macular Degeneration" (1 trials). Many other conditions were trialed in "STZ Eyetrial" in a lesser frequency.

Most popular intervention types in "STZ Eyetrial" are "Drug" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "400 µg Brimonidine Implant" (1 trials), "APL-2" (1 trials), "PEGCETACOPLAN (APL-2)" (1 trials), "Sham" (1 trials) and "Sham Procedure" (1 trials). Other intervention names were less common.

The vast majority of trials in "STZ Eyetrial" are 3 trials for "All" genders.

Currently, there are NaN active trials in "STZ Eyetrial". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in STZ Eyetrial, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in STZ Eyetrial, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".